Jarpe, Matthew

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 616

HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients

Guo, W., Naujock, M., Fumagalli, L., Vandoorne, T., Baatsen, P., Boon, R., Ordovás, L., Patel, A., Welters, M., Vanwelden, T., et al. (2017) · Nature Communications

Amyotrophic Lateral Sclerosis ResearchPluripotent Stem Cells Research

Cited by 373

Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model

Rossaert, E., Pollari, E., Jaspers, T., Van Helleputte, L., Jarpe, M., Van Damme, P., De Bock, K., Moisse, M., & Van Den Bosch, L. (2019) · Acta Neuropathologica Communications

Amyotrophic Lateral Sclerosis ResearchHistone Deacetylase Inhibitors Research

Cited by 93